Details of the Drug Pharmacogenomic Perturbation Atlas

ZD7114 Drug Info

Zeneca ZD7114; ZD7114; ZD 7114; ICI D7114; UNII-EF5S87KTK2; EF5S87KTK2; (S)-4-(2-Hydroxy-3-phenoxypropylaminoethoxy)-N-(2-methoxyethyl)phenoxyacetamide; Acetamide, 2-(4-(2-((2-hydroxy-3-phenoxypropyl)amino)ethoxy)phenoxy)-N-(2-methoxyethyl)-, (S)-; C22H30N2O6; 129689-30-1; AC1L3TKA; SCHEMBL304881; CHEMBL1788312; ICI-D-7114; ZINC3793213; LS-9736; API0009229; 2-[4-[2-[[(2S)-2-hydroxy-3-phenoxypropyl]amino]ethoxy]phenoxy]-N-(2-methoxyethyl)acetamide; NCGC00163153-01; AJ-45629

Cross-matching ID

PubChem CID

121877

CAS Number

CAS 129689-30-1

TTD Drug ID

D05EPU

General Information of Drug (ID: DMZQP7N)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Cell cycle	2.01	8.06e-3	110/124 (88.71%)	E2F2;CCNB2;PLK1;...
Pyruvate metabolism	-1.67	4.75e-2	41/47 (87.23%)	ADH6;GRHPR;MDH2;...
NF-kappa B signaling pathway	-1.67	4.82e-2	90/104 (86.54%)	RELB;TICAM1;TNFSF11;...
Glycolysis / Gluconeogenesis	-1.71	3.49e-2	56/67 (83.58%)	PCK1;BPGM;ENO2;...
Pathogenic Escherichia coli infection	-1.71	3.40e-2	152/197 (77.16%)	ARPC3;TRADD;RPS3;...
Huntington disease	-1.72	3.14e-2	233/306 (76.14%)	NDUFA8;COX7C;APAF1;...
Thermogenesis	-1.72	3.38e-2	173/232 (74.57%)	SIRT6;ATF2;KRAS;...
Rheumatoid arthritis	-1.73	3.56e-2	78/93 (83.87%)	ACP5;ATP6V0C;CXCL5;...
Parkinson disease	-1.76	2.70e-2	176/249 (70.68%)	PSMB2;PSMD13;HTRA2;...
Fatty acid degradation	-1.81	1.78e-2	40/43 (93.02%)	ACSL3;ADH6;ACADM;...
Glyoxylate and dicarboxylate metabolism	-1.98	2.64e-3	23/30 (76.67%)	CS;GRHPR;MDH2;...
Collecting duct acid secretion	-1.98	2.97e-3	22/27 (81.48%)	ATP6V0C;ATP6V0E1;ATP6V0D1;...
Complement and coagulation cascades	-2.02	3.39e-3	76/85 (89.41%)	F3;F7;VWF;...
Glycine, serine and threonine metabolism	-2.02	1.98e-3	31/40 (77.5%)	GAMT;DLD;ALDH7A1;...
Coronavirus disease	-2.04	2.37e-3	215/232 (92.67%)	RPS18;RPL23A;RPS3A;...
Prion disease	-2.07	2.97e-3	209/273 (76.56%)	PRKCD;PPIF;NDUFS3;...
Diabetic cardiomyopathy	-2.14	0.00e+0	162/203 (79.8%)	NDUFS1;PRKCD;PPIF;...
Oxidative phosphorylation	-2.43	0.00e+0	93/133 (69.92%)	ATP5MC3;COX6C;NDUFB6;...
Ribosome	-2.49	0.00e+0	113/158 (71.52%)	RPL37A;RPS6;RPL3L;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.04uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H